| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2012 | US8097650 Method of treating a condition associated with phosphorylation of TASK-1 |
| 01/17/2012 | US8097649 Composition and method for stabilizing the same |
| 01/17/2012 | US8097648 Methods and compositions for use in treating cancer |
| 01/17/2012 | US8097647 Augmented cognitive training |
| 01/17/2012 | US8097646 Ophthalmic preparation containing menthyl ester of indomethacin |
| 01/17/2012 | US8097645 Compounds for activating TGF-β signaling |
| 01/17/2012 | US8097644 Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| 01/17/2012 | US8097643 Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 01/17/2012 | US8097642 Therapeutic inhibitor of vascular smooth muscle cells |
| 01/17/2012 | US8097641 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands |
| 01/17/2012 | US8097640 Prophylactic or therapeutic agent for diabetic maculopathy |
| 01/17/2012 | US8097638 Pyridines for treating injured mammalian nerve tissue |
| 01/17/2012 | US8097637 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors |
| 01/17/2012 | US8097636 Heterocyclic derivatives as modulators of ion channels |
| 01/17/2012 | US8097635 Insulin resistance improving agent |
| 01/17/2012 | US8097634 Azacyclic derivatives |
| 01/17/2012 | US8097633 Treating urinary and fecal incontinence in a patient being treated for a cognitive disorder consisting of one of a group of acute dementia and cognitive impairment by administration of a therapeutic amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist |
| 01/17/2012 | US8097632 Blocking hedgehog protein transduction signal passageway using alkaloid steroid |
| 01/17/2012 | US8097629 Dihydropyridinone derivatives |
| 01/17/2012 | US8097628 Compounds |
| 01/17/2012 | US8097627 Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| 01/17/2012 | US8097626 IL-8 receptor antagonists |
| 01/17/2012 | US8097625 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 01/17/2012 | US8097624 Cycloalkyl derivatives of 3-hydroxy-4-pyridinones |
| 01/17/2012 | US8097623 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics |
| 01/17/2012 | US8097622 Morpholinopurine derivatives |
| 01/17/2012 | US8097621 Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors |
| 01/17/2012 | US8097620 Diazaquinolones that inhibit prolyl hydroxylase activity |
| 01/17/2012 | US8097619 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 01/17/2012 | US8097618 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 01/17/2012 | US8097617 Organic compounds |
| 01/17/2012 | US8097616 Process for preparation of high-purity meloxicam and meloxicam potassium salt |
| 01/17/2012 | US8097615 Neurofibrillary labels |
| 01/17/2012 | US8097614 Transmucosal administration of meloxicam compositions for treating and preventing disorders in non-human domesticated animals |
| 01/17/2012 | US8097613 [1,2,4]thiadiazine 1,1-dioxide compounds |
| 01/17/2012 | US8097612 Compositions and methods relating to novel compounds and targets thereof |
| 01/17/2012 | US8097611 Sulfonyl-derivatives as novel or histone deacetylase |
| 01/17/2012 | US8097610 Derivative having PPAR agonistic activity |
| 01/17/2012 | US8097608 Use of propargylamine or derivative including including N-propargyl-1-aminoindane as protective agent; preventing apoptosis |
| 01/17/2012 | US8097607 loading-dose regimen; an initial administration of rifalazil for 4 to 14 days, followed by less than half this average daily dose for the subsequent 4 to 14 days |
| 01/17/2012 | US8097606 Schizophrenia, Schizoaffective disorder, Obsessive-Compulsive disorder, Personality Disorders and Dissociative Disorders; 11 beta -(4-dimethylaminoethoxyphenyl)-17 alpha -propynyl-17 beta -hydroxy-4,9 estradien-3-one and 17 beta -hydroxy-17 alpha -19-(4-methylphenyl)androsta-4,9(11)-dien-3-one |
| 01/17/2012 | US8097605 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease |
| 01/17/2012 | US8097604 Combination of gestagen and insulin sensitizer for treating PCOS |
| 01/17/2012 | US8097600 Method of increasing tear production with purinergic receptor agonists |
| 01/17/2012 | US8097598 Porcine CTLA-4 for xenograft-specific immunosuppression |
| 01/17/2012 | US8097595 Modulation of telomere length in telomerase positive cells and cancer therapy |
| 01/17/2012 | US8097594 Macrolides and ketolides having antimicrobial activity |
| 01/17/2012 | US8097593 Lipid A and other carbohydrate ligand analogs |
| 01/17/2012 | US8097592 Cocrystal of C-glycoside derivative and L-proline |
| 01/17/2012 | US8097591 Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
| 01/17/2012 | US8097585 Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
| 01/17/2012 | US8097468 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies |
| 01/17/2012 | US8097437 Highly pure polysialic acid and process for preparation thereof |
| 01/17/2012 | US8097343 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents |
| 01/17/2012 | US8097286 Herbal composition weight management |
| 01/17/2012 | US8097282 aqueous dispersion comprising insoluble therapeutic or diagnostic agent particles having a surface modifier; treating a respiratory illness |
| 01/17/2012 | US8097274 Skin substitutes, preparation methods and uses thereof |
| 01/17/2012 | US8097270 Use of nanoparticles as carriers for biocides in ophthalmic compositions |
| 01/17/2012 | US8097267 Moisture resistant container systems for rapidly bioavailable dosage forms |
| 01/17/2012 | US8097265 Foam disinfectant |
| 01/17/2012 | US8097262 Gel type enteral nutrient |
| 01/17/2012 | US8097255 Mammalian receptor protein DCRS5; methods of treatment |
| 01/17/2012 | US8097247 Probiotic, lactic acid-producing bacteria and uses thereof |
| 01/17/2012 | US8097238 Cell targeting conjugates |
| 01/17/2012 | US8097236 The invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable |
| 01/17/2012 | US8096940 Reproductive management |
| 01/17/2012 | US8096419 Compound |
| 01/17/2012 | CA2657594C Pyrrolotriazine kinase inhibitors |
| 01/17/2012 | CA2626767C Heterocyclic substituted pyridine derivatives and antifungal agent containing same |
| 01/17/2012 | CA2611032C 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| 01/17/2012 | CA2602290C Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies |
| 01/17/2012 | CA2559611C Pyrrolidine compounds |
| 01/17/2012 | CA2558139C Tricyclic benzopyran compound as anti-arrhythmic agents |
| 01/17/2012 | CA2534202C Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination |
| 01/17/2012 | CA2531236C Aiding of cognitive function |
| 01/17/2012 | CA2517390C Chroman-derived anti-androgens for treatment of androgen-mediated disorders |
| 01/17/2012 | CA2515370C Compounds with hcv replication inhibition activity |
| 01/17/2012 | CA2504269C Piperazinyl and diazapanyl benzamides and benzthioamides |
| 01/17/2012 | CA2503363C Antioxidative compositions |
| 01/17/2012 | CA2500873C Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 01/17/2012 | CA2499597C Multistage formulation containing a biguanide and thiazolidindione derivatives |
| 01/17/2012 | CA2494846C Arylamides |
| 01/17/2012 | CA2489269C Composition for treatment of inflammatory disorders |
| 01/17/2012 | CA2485852C Agent for binding a plurality of c-reactive protein and their use in the treatment and prevention of tissue damage |
| 01/17/2012 | CA2484640C Vitamin-mitomycin conjugates |
| 01/17/2012 | CA2484269C Compounds and method for coating surfaces in a haemocompatible manner |
| 01/17/2012 | CA2482440C Oligomeric compounds having modified phosphate groups |
| 01/17/2012 | CA2473986C Indazole compounds useful as protein kinase inhibitors |
| 01/17/2012 | CA2470255C N4-acylcytosine nucleosides for treatment of viral infections |
| 01/17/2012 | CA2451353C Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| 01/17/2012 | CA2451244C Purine derivatives as a2b adenosine receptor antagonists |
| 01/17/2012 | CA2429998C Intraocular implants for preventing transplant rejection in the eye |
| 01/17/2012 | CA2418975C Avermectin derivatives |
| 01/17/2012 | CA2413195C Ligand to gpr8 and dna thereof |
| 01/17/2012 | CA2385456C 9-(piperazinylalkyl) carbazoles as bax-modulators |
| 01/17/2012 | CA2379180C Methods for suppressing appetite and enhancing exercise and recovery |
| 01/17/2012 | CA2375214C Surfactant protein c esters |
| 01/17/2012 | CA2345208C Protective recombinant haemophilus influenzae high molecular weight proteins |
| 01/17/2012 | CA2320371C Inotropic and diuretic effects of exendin and glp-1 |
| 01/17/2012 | CA2148712C Peripheralization of hematopoietic stem cells |